glp 1 agonist schizophrenia Semaglutide, a second-generation GLP-1 receptor agonist, was associated with significantly reduced body weight and other metabolic factors in adults with schizophrenia, prediabetes, and overweight/obesity compared with placebo, research from September GLP-1 Agonists - What is

Nielsen, S

Despite strong biological rationale and epidemiologic data, oral semaglutide did not demonstrate clinical benefit in the EVOKE and EVOKE+ trials, underscoring the complexity of translating metabolic repair into cognitive outcomes in established Alzheimers disease

0.0% with placebo, and decreased appetite (19.0% and 18.2%) vs

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy

Some patients respond better to one GLP-1 drug than another due to genetic variation in GLP1R gene expression or differences in how their bodies metabolize each compound

If you are dealing with nausea, bloating, or reflux, reducing these can help significantly